Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 8-K (Current Report)
Date of Report: September 4, 2026
Event: Entry into a Material Definitive Agreement (Asset Purchase Agreement) with Foldlab AI Ltd. to acquire artificial intelligence software, models, source code, data rights, and intellectual property, including the Disease-Associated Protein Discovery AI Agent and the Disease Trend Prediction and Monitoring AI Model.
Key Financial Metrics and Transaction Terms
Total Purchase Price: $4,500,000
Payment Structure:
- Cash Consideration: $2,000,000 total.
- $750,000 payable at closing via wire transfer.
- $1,250,000 in two milestone payments of $625,000 each, contingent upon successful delivery, testing, and acceptance of the AI products.
- Stock Consideration: $2,500,000 in common stock.
- Number of shares calculated based on the 10-day volume-weighted average price (VWAP) prior to closing.
- Shares are subject to a five-year escrow and lock-up with no leak-out.
- Shares are issued under a private-placement exemption and are not registered for resale.
Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company.
Material Changes and Conditions
The transaction represents a material strategic acquisition of AI assets. Closing is subject to several conditions, including:
- Approval by iSpecimen Inc. stockholders (required under Nasdaq Listing Rule 5635(a)).
- Nasdaq approval for the listing of the stock consideration shares.
- Receipt of regulatory approvals and third-party consents.
- Truth and accuracy of seller representations and warranties.
- Absence of any material adverse effect on the transferred assets.
The agreement may be terminated if conditions are not met within 120 days (extendable by 60 days) or in the event of a material uncured breach by the seller.
Guidance, Risks, and Contingencies
Management Commentary: The company intends to file a preliminary proxy statement to seek stockholder approval. The transaction is expected to close promptly after approval is obtained.
Risks and Contingencies:
- Transaction Failure: Risk that stockholder approval is not obtained or closing conditions are not satisfied.
- Performance Risk: Risk that the seller fails to deliver milestone products on time or that the assets do not perform as expected.
- Integration Risk: Risk of unsuccessful integration of the acquired technology.
- Indemnification: Seller indemnifies the company for breaches, IP infringement, and data liabilities. General claims have a $25,000 deductible and a $100,000 cap, though fraud and privacy claims are uncapped.
Investor Verification Checklist
- Verify the outcome of the required stockholder vote for the transaction.
- Confirm the final share count issued based on the VWAP calculation at closing.
- Monitor the status of the two $625,000 milestone payments and the acceptance criteria for the AI products.
- Review the definitive proxy statement for detailed terms and risk factors.
- Check for any regulatory approvals or third-party consents required for the transfer of data rights.